Pharvaris N.V. (PHVS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, CEO & Executive Director | 655.25k | -- | 1959 |
| Mr. David W. Nassif J.D. | CFO, Chief Legal Officer & Corporate Secretary | -- | -- | 1954 |
| Ms. Anna Nijdam M.Sc., R.A. | Head of Strategic Finance & Principal Accounting Officer | -- | -- | 1981 |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer | -- | -- | 1970 |
| Ms. Annick Deschoolmeester | Chief Human Resources Officer | -- | -- | 1973 |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer | -- | -- | 1978 |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer | -- | -- | 1961 |
| Mr. Wim Souverijns Ph.D. | Chief Commercial Officer | -- | -- | 1971 |
| Maryann Cimino | Director of Corporate Relations | -- | -- | -- |
Pharvaris N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 108
Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Corporate Governance
Upcoming Events
August 12, 2025 at 8:00 PM UTC - August 18, 2025 at 8:00 PM UTC
Pharvaris N.V. Earnings Date